See more : Data Knights Acquisition Corp. (DKDCW) Income Statement Analysis – Financial Results
Complete financial analysis of RVL Pharmaceuticals plc (RVLPQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RVL Pharmaceuticals plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Huarong International Financial Holdings Limited (0993.HK) Income Statement Analysis – Financial Results
- Scentre Group (SCG.AX) Income Statement Analysis – Financial Results
- CIR S.p.A. – Compagnie Industriali Riunite (CIR.MI) Income Statement Analysis – Financial Results
- G Squared Ascend I Inc. (GSQD) Income Statement Analysis – Financial Results
- Skyharbour Resources Ltd. (SYH.V) Income Statement Analysis – Financial Results
RVL Pharmaceuticals plc (RVLPQ)
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 49.72M | 17.50M | 27.76M | 240.03M | 263.70M | 245.75M | 218.46M |
| Cost of Revenue | 9.46M | 3.62M | 3.29M | 111.63M | 141.96M | 126.28M | 126.85M |
| Gross Profit | 40.27M | 13.88M | 24.47M | 128.40M | 121.75M | 119.47M | 91.61M |
| Gross Profit Ratio | 80.98% | 79.33% | 88.14% | 53.49% | 46.17% | 48.61% | 41.94% |
| Research & Development | 3.97M | 6.93M | 13.39M | 32.32M | 43.69M | 42.69M | 29.06M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.98M | 87.46M | 72.82M | 93.03M | 72.37M | 55.86M | 61.52M |
| Other Expenses | 13.31M | -1.33M | -48.00K | 884.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 99.26M | 94.39M | 86.21M | 125.35M | 116.06M | 98.55M | 90.59M |
| Cost & Expenses | 108.71M | 98.01M | 89.50M | 236.98M | 258.02M | 224.83M | 217.43M |
| Interest Income | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.02M | 4.10M | 18.21M | 20.79M | 29.05M | 20.19M |
| Depreciation & Amortization | 375.00K | 8.18M | 21.03M | 57.02M | 81.60M | 46.45M | 23.59M |
| EBITDA | -48.23M | -70.34M | -69.67M | -222.80M | -16.28M | -10.14M | -8.29M |
| EBITDA Ratio | -97.00% | -420.94% | -146.83% | 25.39% | 33.10% | 27.41% | 11.27% |
| Operating Income | -58.99M | -82.75M | -90.65M | -280.70M | 5.68M | 20.92M | 1.03M |
| Operating Income Ratio | -118.64% | -472.85% | -326.53% | -116.94% | 2.16% | 8.51% | 0.47% |
| Total Other Income/Expenses | 7.28M | 220.00K | -4.14M | -17.33M | -20.13M | -106.56M | -53.10M |
| Income Before Tax | -51.71M | -82.53M | -94.80M | -298.02M | -118.66M | -85.64M | -52.07M |
| Income Before Tax Ratio | -104.00% | -471.60% | -341.46% | -124.16% | -45.00% | -34.85% | -23.83% |
| Income Tax Expense | -20.00K | 315.00K | -5.78M | -27.12M | -8.98M | -44.50M | -10.25M |
| Net Income | -51.69M | -64.92M | -79.59M | -270.90M | -109.68M | -41.14M | -41.82M |
| Net Income Ratio | -103.96% | -370.95% | -286.68% | -112.86% | -41.59% | -16.74% | -19.14% |
| EPS | -0.58 | -0.96 | -1.31 | -5.17 | -2.42 | -0.96 | -0.80 |
| EPS Diluted | -0.58 | -0.96 | -1.31 | -5.17 | -2.42 | -0.96 | -0.80 |
| Weighted Avg Shares Out | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 52.52M |
| Weighted Avg Shares Out (Dil) | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 52.52M |
Source: https://incomestatements.info
Category: Stock Reports